ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematological-malignancies-multiple-myeloma-in-the-covid-19-era Accessed 19 April 2020. von Lilienfeld-Toal M, Greini...
the introduction of novel agents such as thalidomide, lenalidomide, and the proteasome inhibitor bortezomib, which are associated with high-dose therapy and autologous stem cell transplantation in young patients and standard chemotherapy in elderly patients, has changed the management of myeloma and extend...
Current guidelines for smoldering multiple myeloma (SMM) recommend active monitoring until the onset of multiple myeloma (MM) before initiating treatment or enrollment in a clinical trial. Earlier intervention may delay progression to MM. In CENTAURUS, 1
Over the past 13 years, there have been advances in characterizing the patient experience in oncology trials, primarily using patient-reported outcomes (PROs). This review aims to provide details on the PRO measures and analyses used in multiple myeloma (MM) registrational trials. We identified re...
Multiple myeloma (MM) is a plasma cell malignancy in which monoclonal plasma cells proliferate in bone marrow, resulting in an overabundance of monoclonal paraprotein (M protein), destruction of bone, and displacement of other hematopoietic cell lines. [1] First described in 1848, MM is part of...
Minimal residual disease in multiple myeloma: bringing the bench to the bedside. Nat Rev Clin Oncol. 2015;12(5):286-295.PubMedGoogle ScholarCrossref 4. Biran N, Ely S, Chari A. Controversies in the assessment of minimal residual disease in multiple myeloma: clinical significance of minimal...
Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models. Monotherapy with PD-1 inhibitors produced d
PDF Tools Share Abstract The recently updated Durie/Salmon PLUS staging system published in 2006 highlights the many advances that have been made in the imaging of multiple myeloma, a common malignancy of plasma cells. In this article, we shall focus primarily on the more sensitive and specific ...
Multiple myeloma (MM), a B-cell malignancy with accumulation of clonal, malignant plasma cells in the bone marrow, is the second most common haematological malignancy affecting over 20 000 patients each year in the United States.1 Although, allogeneic bone marrow transplantation is still ...
Cell adhesion in the multiple myeloma (MM) microenvironment has been recognized as a major mechanism of MM cell survival and the development of drug resistance. Here we addressed the hypothesis that the protein junctional adhesion molecule-A (JAM-A) may represent a novel target and a clinical bi...